New business areas - orthopaedics and aesthetics
Along with the steady growth of the company, Croma Pharma® started to research and develop its own products. In the year 2002, it produced the first viscoelastics for the treatment of arthrosis. Further segments were then developed. After founding the first branches abroad in 2007, the Swiss company Xcelens® was acquired. Shortly thereafter, Croma Pharma® took over the French manufacturer Cornéal® . These investments helped Croma Pharma® to expand its international product portfolio in the ophthalmological segment significantly. The portfolio was also expanded by the dermatological aesthetics segment. The brand Princess® was successfully established. These hyaluronic acid syringes were used for minimally invasive beauty treatments. This was an international trend, recognized early on, which developed into the core business over the following years. Together with Bausch & Lomb, Croma Pharma® distributed the innovative, non-steroidal anti-inflammatory agent Yellox® . As the years went by, Yellox® became an international bestseller. As part of a comprehensive strategic re-orientation, the focus was placed on minimally invasive aesthetic treatments. Croma Pharma® sold its product portfolio in the segments of ophthalmology and orthopaedics to Valeant Pharmaceuticals. Croma Pharma® continues to operate as a producer of hyaluronic acid within these segments.